DK1175401T3 - Piperazinderivater, der er nyttige som CCR5-antagonister - Google Patents
Piperazinderivater, der er nyttige som CCR5-antagonisterInfo
- Publication number
- DK1175401T3 DK1175401T3 DK00926486T DK00926486T DK1175401T3 DK 1175401 T3 DK1175401 T3 DK 1175401T3 DK 00926486 T DK00926486 T DK 00926486T DK 00926486 T DK00926486 T DK 00926486T DK 1175401 T3 DK1175401 T3 DK 1175401T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivatives useful
- piperazine derivatives
- ccr5 antagonists
- ccr5
- antagonists
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000004885 piperazines Chemical class 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30522699A | 1999-05-04 | 1999-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1175401T3 true DK1175401T3 (da) | 2005-11-14 |
Family
ID=23179892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00926486T DK1175401T3 (da) | 1999-05-04 | 2000-05-01 | Piperazinderivater, der er nyttige som CCR5-antagonister |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1632479B1 (ru) |
JP (2) | JP3722700B2 (ru) |
KR (1) | KR100439358B1 (ru) |
AR (5) | AR023823A1 (ru) |
AT (2) | ATE299865T1 (ru) |
AU (2) | AU780888B2 (ru) |
BR (1) | BR0010304A (ru) |
CA (1) | CA2371583C (ru) |
CH (1) | CH1175401H9 (ru) |
CL (1) | CL2008002737A1 (ru) |
CO (1) | CO5170523A1 (ru) |
CZ (1) | CZ20013940A3 (ru) |
DE (2) | DE60021370C5 (ru) |
DK (1) | DK1175401T3 (ru) |
EG (1) | EG24136A (ru) |
ES (1) | ES2244437T3 (ru) |
HK (1) | HK1039930B (ru) |
HU (1) | HUP0202867A3 (ru) |
IL (1) | IL145741A0 (ru) |
MY (1) | MY128367A (ru) |
NO (1) | NO322045B1 (ru) |
PE (1) | PE20010150A1 (ru) |
PL (1) | PL203116B1 (ru) |
RU (1) | RU2299206C9 (ru) |
SA (2) | SA06270096B1 (ru) |
SI (1) | SI1175401T1 (ru) |
SK (2) | SK286641B6 (ru) |
TR (1) | TR200103214T2 (ru) |
TW (1) | TWI285200B (ru) |
WO (1) | WO2000066558A1 (ru) |
ZA (1) | ZA200108868B (ru) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7825121B2 (en) | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
SI1373256T1 (sl) | 2001-03-29 | 2005-12-31 | Schering Corp | Antagonisti CCR5, uporabni pri zdravljenju AIDS-a |
HUP0400389A3 (en) * | 2001-03-29 | 2008-03-28 | Schering Corp | Aryl oxime-piperazines useful as ccr5 antagonists and pharmaceutical compositions containing them |
WO2003048153A1 (en) * | 2001-11-29 | 2003-06-12 | Schering Corporation | Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers |
EP2311818B1 (en) | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
JP4671091B2 (ja) * | 2002-03-18 | 2011-04-13 | 東レ・ファインケミカル株式会社 | 1−置換−2−メチルピペラジンの製造方法 |
US6992189B2 (en) * | 2002-03-29 | 2006-01-31 | Schering Corporation | Synthesis of piperidine and piperazine compounds as CCR5 antagonists |
CN100343240C (zh) * | 2002-03-29 | 2007-10-17 | 先灵公司 | 手性2-甲基-4-保护的哌嗪的立体选择性烷基化 |
EP1498125A4 (en) * | 2002-04-24 | 2008-08-20 | Takeda Pharmaceutical | USE OF ANTI-CCR ANTAGONISM COMPOUNDS |
JP2003335737A (ja) | 2002-05-21 | 2003-11-28 | Central Glass Co Ltd | 光学活性(r)−1−(4−トリフルオロメチルフェニル)エチルアミン |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
US20060251651A1 (en) * | 2002-12-13 | 2006-11-09 | Ono Pharmaceutical Co., Ltd. | Antagonist and agonist which bind to a strong binding site of chemokine receptor |
PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
MXPA05009771A (es) | 2003-03-14 | 2005-10-26 | Ono Pharmaceutical Co | Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo. |
WO2004092136A1 (ja) * | 2003-04-18 | 2004-10-28 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその用途 |
EP1619193A4 (en) | 2003-04-18 | 2010-08-11 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
GB0313661D0 (en) * | 2003-06-13 | 2003-07-16 | Avecia Ltd | Process |
EP1633737A1 (en) * | 2003-06-13 | 2006-03-15 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
CA2526725A1 (en) | 2003-06-30 | 2005-01-20 | Schering Corporation | Mch antagonists for the treatment of obesity |
ATE520683T1 (de) | 2003-11-03 | 2011-09-15 | Schering Corp | Als inhibitoren von chemokinrezeptoren geeignete bipiperidinylderivate |
GB0329284D0 (en) * | 2003-12-18 | 2004-01-21 | Avecia Ltd | Process |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
ES2324224T3 (es) * | 2004-02-05 | 2009-08-03 | Schering Corporation | Derivados de piperidina que se pueden utilizar como antagonistas ccr3. |
AU2005211499A1 (en) | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine CCR5 receptor modulators |
CA2558848C (en) | 2004-03-05 | 2013-11-19 | Nissan Chemical Industries, Ltd. | Isoxazoline-substituted benzamide compound and pesticide |
AU2005234596B8 (en) * | 2004-04-13 | 2011-06-16 | Incyte Holdings Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
BRPI0511982A (pt) | 2004-06-09 | 2008-01-22 | Hoffmann La Roche | compostos antiviróticos heterocìclicos |
GB0417804D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
RU2409565C2 (ru) | 2004-09-13 | 2011-01-20 | Оно Фармасьютикал Ко., Лтд. | Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
MX2007006695A (es) | 2004-12-03 | 2007-08-14 | Schering Corp | Piperazinas sustituidas como antagonistas de cb1. |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071875A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
JP2008526862A (ja) * | 2005-01-06 | 2008-07-24 | シェーリング コーポレイション | ピペラジン化合物の薬学的な塩の調製 |
WO2006088840A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity |
CA2598457A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
ATE523506T1 (de) * | 2005-02-16 | 2011-09-15 | Schering Corp | Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität |
MX2007009947A (es) * | 2005-02-16 | 2007-09-26 | Schering Corp | Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3. |
EP1858895B1 (en) * | 2005-02-16 | 2012-06-20 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
AU2006216731A1 (en) * | 2005-02-23 | 2006-08-31 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
ES2330788T3 (es) | 2005-06-02 | 2009-12-15 | F. Hoffmann-La Roche Ag | Derivados de piperidin-4-il-amida y su uso como antagonistas del subtipo 5 del receptor sst. |
US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
BRPI0617720A2 (pt) | 2005-10-19 | 2011-08-02 | Hoffmann La Roche | compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém |
AR058104A1 (es) | 2005-10-21 | 2008-01-23 | Novartis Ag | Compuestos organicos |
PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
PL1961744T3 (pl) | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową oraz jego zastosowanie |
WO2007064620A2 (en) * | 2005-11-30 | 2007-06-07 | Schering Corporation | Compositions comprising a combination of ccr5 and cxcr4 antagonists |
GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
MX2008009354A (es) | 2006-01-18 | 2008-09-30 | Schering Corp | Moduladores de receptores cannabinoides. |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US8003642B2 (en) | 2006-03-10 | 2011-08-23 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
PL2322525T3 (pl) | 2006-04-21 | 2014-03-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub> |
WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
EP2057125B1 (en) | 2006-08-16 | 2011-03-30 | F. Hoffmann-La Roche AG | Non-nucleoside reverse transcriptase inhibitors |
RU2009115954A (ru) | 2006-09-29 | 2010-11-10 | Новартис АГ (CH) | Пиразолопиримидины в качестве ингибиторов липидной киназы р13к |
ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
GB0625523D0 (en) * | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
EP2104535B9 (en) | 2007-01-10 | 2011-06-15 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2137162B1 (en) | 2007-03-15 | 2018-08-01 | Novartis AG | Organic compounds and their uses |
WO2008119663A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
AU2008248598B2 (en) | 2007-05-07 | 2011-11-17 | Novartis Ag | Organic compounds |
WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
BRPI0817935A2 (pt) | 2007-10-01 | 2015-04-07 | Hoffmann La Roche | Derivados de biarila |
MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
AU2009220462A1 (en) * | 2008-02-29 | 2009-09-11 | Merck Sharp & Dohme Corp. | CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US8367674B2 (en) | 2008-04-17 | 2013-02-05 | Concert Pharmaceuticals, Inc. | Piperazine derivatives |
AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
HUE025547T2 (en) | 2008-12-19 | 2016-02-29 | Boehringer Ingelheim Int | Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD |
DK2391366T3 (da) | 2009-01-29 | 2013-01-07 | Novartis Ag | Substituerede benzimidazoler til behandling af astrocytomer |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
AU2010284254B2 (en) | 2009-08-17 | 2015-09-17 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
CA2777245A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
PE20121614A1 (es) | 2009-12-17 | 2012-12-21 | Boehringer Ingelheim Int | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 |
US20130143905A1 (en) * | 2009-12-17 | 2013-06-06 | Boehringer Ingelheim International Gmbh | Novel antagonists for ccr2 and uses thereof |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
KR101491938B1 (ko) | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ip 수용체 효능제 헤테로시클릭 화합물 |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なccr2拮抗薬 |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン |
ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
EP2802583A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
EP2802585A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
CN104053659B (zh) | 2012-01-13 | 2016-11-09 | 诺华股份有限公司 | 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类 |
EP2802582A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
JP6058698B2 (ja) | 2012-01-13 | 2017-01-11 | ノバルティス アーゲー | Ip受容体アゴニストの塩 |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
US9227990B2 (en) | 2012-10-29 | 2016-01-05 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
US9604981B2 (en) | 2013-02-13 | 2017-03-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
ES2761569T3 (es) | 2014-04-24 | 2020-05-20 | Novartis Ag | Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas |
EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
JP6633618B2 (ja) * | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 強力なrock阻害剤としてのタイドバックのベンズアミド誘導体 |
BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
KR20220052934A (ko) | 2019-08-28 | 2022-04-28 | 노파르티스 아게 | 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
JP2002510327A (ja) * | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
CA2336000C (en) * | 1998-06-30 | 2006-10-10 | Schering Corporation | N-substituted piperazines and 1,4-disubstituted piperidines |
-
2000
- 2000-05-01 HU HU0202867A patent/HUP0202867A3/hu unknown
- 2000-05-01 DK DK00926486T patent/DK1175401T3/da active
- 2000-05-01 EP EP05010936A patent/EP1632479B1/en not_active Expired - Lifetime
- 2000-05-01 RU RU2001132632/04A patent/RU2299206C9/ru not_active IP Right Cessation
- 2000-05-01 AU AU45009/00A patent/AU780888B2/en not_active Expired
- 2000-05-01 AT AT00926486T patent/ATE299865T1/de not_active IP Right Cessation
- 2000-05-01 SK SK1569-2001A patent/SK286641B6/sk not_active IP Right Cessation
- 2000-05-01 ES ES00926486T patent/ES2244437T3/es not_active Expired - Lifetime
- 2000-05-01 SK SK5124-2007A patent/SK287418B6/sk not_active IP Right Cessation
- 2000-05-01 CH CH926486.2T patent/CH1175401H9/de unknown
- 2000-05-01 SI SI200030718T patent/SI1175401T1/xx unknown
- 2000-05-01 KR KR10-2001-7013863A patent/KR100439358B1/ko not_active IP Right Cessation
- 2000-05-01 DE DE60021370T patent/DE60021370C5/de not_active Expired - Lifetime
- 2000-05-01 AT AT05010936T patent/ATE495154T1/de not_active IP Right Cessation
- 2000-05-01 IL IL14574100A patent/IL145741A0/xx unknown
- 2000-05-01 EP EP00926486A patent/EP1175401B1/en not_active Expired - Lifetime
- 2000-05-01 CZ CZ20013940A patent/CZ20013940A3/cs unknown
- 2000-05-01 BR BR0010304-7A patent/BR0010304A/pt not_active IP Right Cessation
- 2000-05-01 DE DE60045528T patent/DE60045528D1/de not_active Expired - Lifetime
- 2000-05-01 JP JP2000615389A patent/JP3722700B2/ja not_active Expired - Lifetime
- 2000-05-01 PL PL351388A patent/PL203116B1/pl not_active IP Right Cessation
- 2000-05-01 CA CA002371583A patent/CA2371583C/en not_active Expired - Lifetime
- 2000-05-01 WO PCT/US2000/011632 patent/WO2000066558A1/en active Search and Examination
- 2000-05-01 TR TR2001/03214T patent/TR200103214T2/xx unknown
- 2000-05-02 PE PE2000000407A patent/PE20010150A1/es not_active Application Discontinuation
- 2000-05-02 CO CO00031259A patent/CO5170523A1/es not_active Application Discontinuation
- 2000-05-02 EG EG20000563D patent/EG24136A/xx active
- 2000-05-02 MY MYPI20001892A patent/MY128367A/en unknown
- 2000-05-02 TW TWPIPERAZINA patent/TWI285200B/zh active
- 2000-05-02 AR ARP000102096A patent/AR023823A1/es active IP Right Grant
- 2000-08-05 SA SA06270096A patent/SA06270096B1/ar unknown
- 2000-08-05 SA SA00210271A patent/SA00210271B1/ar unknown
-
2001
- 2001-10-26 ZA ZA200108868A patent/ZA200108868B/xx unknown
- 2001-11-02 NO NO20015366A patent/NO322045B1/no not_active IP Right Cessation
-
2002
- 2002-02-02 HK HK02100824.0A patent/HK1039930B/zh not_active IP Right Cessation
-
2005
- 2005-05-31 AU AU2005202357A patent/AU2005202357B2/en not_active Expired
- 2005-08-16 JP JP2005236161A patent/JP2006052225A/ja not_active Withdrawn
-
2006
- 2006-08-30 AR ARP060103793A patent/AR057106A2/es unknown
- 2006-08-30 AR ARP060103794A patent/AR057107A2/es unknown
- 2006-08-30 AR ARP060103792A patent/AR057786A2/es unknown
- 2006-11-03 AR ARP060104839A patent/AR057873A2/es active IP Right Grant
-
2008
- 2008-09-15 CL CL2008002737A patent/CL2008002737A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1175401T3 (da) | Piperazinderivater, der er nyttige som CCR5-antagonister | |
DK1175402T3 (da) | Piperidinderivater, der er nyttige som CCR5-antagonister | |
NO20021459D0 (no) | Piperazin-derivater som 5-HT1B-antagonister | |
DK1218359T3 (da) | Piperazinforbindelser som tachykininantagonister | |
NO20021450D0 (no) | Cykliske aminforbindelser som CCR5 antagonister | |
NO20013671L (no) | Substituerte bisycliske derivater nyttige som anticancer midler | |
DK1309559T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
DK1421075T3 (da) | Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV | |
DK1305319T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
NO20032142L (no) | Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister | |
NO20021251D0 (no) | Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister | |
DK1155013T3 (da) | Heyterocycliske benzensulfonamidderivater som bradykininantagonister | |
NO20023001D0 (no) | Substituerte piperazinderivater som MTP inhibitorer | |
PT1176144E (pt) | Novos derivados de n-triazolilmetil piperazina como antagonistas do receptor da neuroquinina | |
NO992066D0 (no) | Piperazinoderivater som neurokininantagonister | |
DK1015446T3 (da) | 4-(Piperidinyl)-1H-2-benzopyranderivater, der er nyttige som antipsykotiske midler | |
DK1456197T3 (da) | Piperidin-2,6-dioner, som er substitueret heterocyklisk i 3-stillingen | |
SI1216239T1 (en) | Piperazine derivatives as 5-ht1b antagonists | |
DK1207159T3 (da) | Heteroaromatiske derivater som dopamin-D4-receptorantagonister |